Resveratrol Derivative Exhibits Marked Antiproliferative Actions, Affecting Stemness in Pancreatic Cancer Cells.
CD133
EpCAM
natural compounds
pancreatic ductal adenocarcinoma
phytoalexin
polyphenols
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Jan 2023
19 Jan 2023
Historique:
received:
16
12
2022
revised:
10
01
2023
accepted:
17
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Pancreatic cancer (PC) is one of the deadliest malignancies, with an increasing incidence and limited response to current therapeutic options. Therefore, more effective and low-toxic agents are needed to improve PC patients' outcomes. Resveratrol (RSV) is a natural polyphenol with multiple biological properties, including anticancer effects. In this study, we explored the antiproliferative activities of newly synthetized RSV analogues in a panel of PC cell lines and evaluated the physicochemical properties of the most active compound. This derivative exhibited marked antiproliferative effects in PC cells through mechanisms involving DNA damage, apoptosis induction, and interference in cell cycle progression, as assessed using flow cytometry and immunoblot analysis of cell cycle proteins, PARP cleavage, and H2AX phosphorylation. Notably, the compound induced a consistent reduction in the PC cell subpopulation with a CD133
Identifiants
pubmed: 36768301
pii: ijms24031977
doi: 10.3390/ijms24031977
pmc: PMC9916441
pii:
doi:
Substances chimiques
Polyphenols
0
Resveratrol
Q369O8926L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of University and Research, Progetti di Ricerca di Interesse Nazionale (PRIN) funds
ID : 2017EKMFTN_005
Références
Cell Prolif. 2019 Jan;52(1):e12514
pubmed: 30341797
Biomed Res Int. 2017;2017:8412508
pubmed: 28232946
Surg Oncol. 2022 Aug;43:101803
pubmed: 35830772
Ann N Y Acad Sci. 2015 Aug;1348(1):10-9
pubmed: 26284849
J Nanobiotechnology. 2022 Jul 20;20(1):339
pubmed: 35858935
Mol Cell. 2006 Jul 7;23(1):121-32
pubmed: 16818236
Antibiotics (Basel). 2020 Dec 10;9(12):
pubmed: 33322025
ChemMedChem. 2017 Apr 20;12(8):558-570
pubmed: 28266812
Sci Rep. 2018 Sep 11;8(1):13610
pubmed: 30206358
Eur J Immunol. 2021 Dec;51(12):2708-3145
pubmed: 34910301
Endocr Relat Cancer. 2014 May 06;21(3):R209-25
pubmed: 24500760
Carcinogenesis. 2005 Nov;26(11):1978-87
pubmed: 15975956
Eur J Med Chem. 2015 Jan 27;90:1-9
pubmed: 25461306
Eur J Med Chem. 2019 Sep 15;178:515-529
pubmed: 31207463
Medicina (Kaunas). 2022 Jul 22;58(8):
pubmed: 35893093
Clin Cancer Res. 2002 Mar;8(3):893-903
pubmed: 11895924
Drug Des Devel Ther. 2018 Mar 07;12:475-480
pubmed: 29563772
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancer Res. 2007 Mar 15;67(6):2685-92
pubmed: 17363589
Front Cell Dev Biol. 2022 May 16;10:855474
pubmed: 35652096
Cancers (Basel). 2019 Dec 17;11(12):
pubmed: 31861153
Biomolecules. 2020 Jul 27;10(8):
pubmed: 32726968
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
World J Clin Oncol. 2016 Feb 10;7(1):27-43
pubmed: 26862489
Nutrients. 2021 Oct 26;13(11):
pubmed: 34836055
Lancet. 2020 Jun 27;395(10242):2008-2020
pubmed: 32593337
Sci Rep. 2016 Aug 19;6:31672
pubmed: 27539371
Ann N Y Acad Sci. 2017 Sep;1403(1):59-69
pubmed: 28945938
Cancers (Basel). 2021 Jun 11;13(12):
pubmed: 34208295
Phytother Res. 2010 Nov;24(11):1637-44
pubmed: 21031621
Pharmaceuticals (Basel). 2021 Sep 27;14(10):
pubmed: 34681208
Int J Cancer. 2010 Jul 15;127(2):257-68
pubmed: 19908231
Eur J Med Chem. 2016 Jan 27;108:553-563
pubmed: 26717205
Drug Dev Ind Pharm. 2015;41(9):1464-9
pubmed: 25224342
Front Pharmacol. 2021 Oct 20;12:710304
pubmed: 34744708
PLoS One. 2017 Jun 8;12(6):e0178995
pubmed: 28594934
Int J Pharm. 2022 Apr 25;618:121605
pubmed: 35227804
J Exp Clin Cancer Res. 2018 Sep 21;37(1):236
pubmed: 30241558
Pancreas. 2002 Nov;25(4):e71-6
pubmed: 12409844
Drug Metab Dispos. 2004 Dec;32(12):1377-82
pubmed: 15333514
Mol Biol Rep. 2019 Dec;46(6):6629-6645
pubmed: 31486978
PLoS One. 2016 Jul 14;11(7):e0159255
pubmed: 27414409
PLoS One. 2011 Jan 31;6(1):e16530
pubmed: 21304978
Pharmaceuticals (Basel). 2021 Apr 17;14(4):
pubmed: 33920661
Molecules. 2021 Oct 29;26(21):
pubmed: 34770968
Anticancer Res. 2004 Sep-Oct;24(5A):2783-840
pubmed: 15517885
Eur J Med Chem. 2020 Jan 15;186:111880
pubmed: 31753513
Cancers (Basel). 2021 Aug 05;13(16):
pubmed: 34439102
Eur J Med Chem. 2009 Apr;44(4):1644-9
pubmed: 18976835
Sci Rep. 2018 Apr 11;8(1):5823
pubmed: 29643468
Bioorg Med Chem Lett. 1998 Nov 17;8(22):3187-92
pubmed: 9873700
Molecules. 2020 Dec 07;25(23):
pubmed: 33297520
Cancers (Basel). 2022 Mar 07;14(5):
pubmed: 35267665
Methods Mol Biol. 2018;1692:89-95
pubmed: 28986889
Int J Oncol. 2017 Mar;50(3):787-797
pubmed: 28197625